miR Scientific

miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization and monitoring of disease. The Company has developed the miR Disease Management Platform®, a proprietary, non-invasive platform for the effective management of targeted diseases, initially focused on urological cancers. The platform powers the miR Sentinel™ Prostate Cancer Test, a liquid biopsy urine test that accurately detects, classifies and can monitor prostate cancer based on the interrogation of sncRNAs extracted from non-DRE urinary exosomes. miR Scientific is developing interoperable products and services necessary to revolutionize the standards of care supporting urologic oncology, including prostate, bladder and other urothelial cancers. Such new standards are urgently needed given the prevalence of these cancers and their debilitating burden globally. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in New York City with operating subsidiaries in Israel, Japan, Canada, and Puerto Rico.